Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Gains from Sales and Divestitures (2024 - 2025)

Apyx Medical (APYX) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 37.31% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Dec 2025, up 37.31%, and an annual FY2025 reading of $1.5 million, up 37.31% over the prior year.
  • Gains from Sales and Divestitures was $1.5 million for Q4 2025 at Apyx Medical, up from $1.1 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.5 million in Q4 2025 and bottomed at $1.1 million in Q4 2024.